KRAS and cancer: The present study established a link between Kras active mutation and beta‐catenin/TCF signalling, and indicated that targeting the TM4SF1‐mediated activation of the beta‐catenin/TCF cascade might be helpful for the therapy of KrasG12D‐driven cancer.